5 things about AI you may have missed today: Doctors for free in a decade, tech giants fund Congressional AI fellows
It has been alleged that tech giants fund Congressional AI fellows and this has raised concerns of undue industry influence; AstraZeneca Inks $247 million deal with AI firm Absci for cancer drug discovery; MediaTek's on-device AI promises to personalised phone experience; EY's AI detects fraud in UK audits- this and more in our daily roundup. Let us take a look.
Tech giants like Google, Microsoft, IBM, and Nvidia are funnelling funds through the American Association for the Advancement of Science to support a "rapid response cohort" of Congressional AI fellows. These fellows, including PhD holders and former tech professionals, are influencing AI policy in Senate offices, including those of Sens. Schumer, Heinrich, Rounds, Wyden, Cassidy, and Kelly. The move raises concerns about potential industry influence on AI regulation, according to a Politico.com report.
AstraZeneca has partnered with Absci Corporation in a $247 million deal to leverage AI technology for cancer drug discovery. Absci's AI conducts large-scale protein analysis, aiding AstraZeneca's focus on oncology therapies. The collaboration exemplifies the growing trend of big pharmaceutical companies utilising AI for novel disease treatments. Absci's generative AI model, trained on proprietary protein interaction data, contributes to antibody design. The undisclosed cancer target aligns with AstraZeneca's goal to advance targeted drugs over traditional chemotherapy, emphasising AI's role in enhancing biologics discovery, Financial Times reported.
MediaTek aims to revolutionise phones with on-device AI, promising personalised answers and faster suggestions. The company's generative AI technology, highlighted at its Executive Summit, enables features like Vivo's
Read more on tech.hindustantimes.com
